Mediclinic International Toekomstige groei

Future criteriumcontroles 2/6

Mediclinic International zal naar verwachting groeien in winst en omzet met respectievelijk 10.7% en 3.6% per jaar. De winst per aandeel zal naar verwachting groeien met 12.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 6.6% zijn.

Belangrijke informatie

10.7%

Groei van de winst

12.2%

Groei van de winst per aandeel

Healthcare winstgroei	23.3%
Inkomstengroei	3.6%
Toekomstig rendement op eigen vermogen	6.6%
Dekking van analisten	Good
Laatst bijgewerkt	30 May 2023

Recente toekomstige groei-updates

Mediclinic International plc (LON:MDC) Could Be Less Than A Year Away From Profitability

Feb 11

Recent updates

Here's Why We Think Mediclinic International (LON:MDC) Might Deserve Your Attention Today

Jul 26

Is There An Opportunity With Mediclinic International plc's (LON:MDC) 25% Undervaluation?

Sep 08

Is Mediclinic International (LON:MDC) Using Too Much Debt?

Jun 21

Does This Valuation Of Mediclinic International plc (LON:MDC) Imply Investors Are Overpaying?

May 26

If You Had Bought Mediclinic International's (LON:MDC) Shares Five Years Ago You Would Be Down 63%

Mar 17

What Kind Of Shareholders Hold The Majority In Mediclinic International plc's (LON:MDC) Shares?

Feb 26

Mediclinic International plc (LON:MDC) Could Be Less Than A Year Away From Profitability

Feb 11

Have Mediclinic International plc (LON:MDC) Insiders Been Selling Their Stock?

Jan 27

Estimating The Fair Value Of Mediclinic International plc (LON:MDC)

Jan 18

These 4 Measures Indicate That Mediclinic International (LON:MDC) Is Using Debt Extensively

Jan 01

A Look At Mediclinic International's (LON:MDC) Share Price Returns

Dec 17

Our View On Mediclinic International's (LON:MDC) CEO Pay

Dec 02

Winst- en omzetgroeiprognoses

LSE:MDC - Toekomstschattingen van analisten en financiële gegevens uit het verleden (GBP Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2026	3,888	271	N/A	N/A	1
3/31/2025	3,684	255	330	551	6
3/31/2024	3,564	237	309	525	6
3/31/2023	3,441	212	183	422	6
9/30/2022	3,383	169	283	470	N/A
6/30/2022	3,308	160	329	512	N/A
3/31/2022	3,233	151	375	554	N/A
12/31/2021	3,199	135	321	483	N/A
9/30/2021	3,165	118	266	412	N/A
6/30/2021	3,080	93	183	324	N/A
3/31/2021	2,995	68	99	235	N/A
12/31/2020	2,987	-173	N/A	N/A	N/A
9/30/2020	2,979	-414	133	306	N/A
6/30/2020	3,031	-367	203	381	N/A
3/31/2020	3,083	-320	273	456	N/A
12/31/2019	3,070	-97	N/A	N/A	N/A
9/30/2019	3,057	126	246	443	N/A
6/30/2019	2,995	-12	175	394	N/A
3/31/2019	2,932	-151	104	344	N/A
12/31/2018	2,897	-380	N/A	N/A	N/A
9/30/2018	2,861	-610	23	277	N/A
6/30/2018	2,869	-551	57	311	N/A
3/31/2018	2,876	-492	91	345	N/A
12/31/2017	2,874	-211	N/A	N/A	N/A
9/30/2017	2,871	69	97	350	N/A
6/30/2017	2,810	149	121	364	N/A
3/31/2017	2,749	229	145	377	N/A
12/31/2016	2,565	210	155	375	N/A
9/30/2016	2,380	191	165	373	N/A
6/30/2016	2,244	184	N/A	347	N/A
3/31/2016	2,107	177	N/A	320	N/A
12/31/2015	2,080	211	N/A	314	N/A
9/30/2015	2,183	257	N/A	330	N/A
6/30/2015	2,042	245	N/A	327	N/A
3/31/2015	1,977	241	N/A	337	N/A
12/31/2014	1,901	221	N/A	312	N/A
9/30/2014	1,810	199	N/A	284	N/A
6/30/2014	1,751	193	N/A	270	N/A
3/31/2014	1,738	193	N/A	263	N/A
12/31/2013	1,652	82	N/A	253	N/A
9/30/2013	1,653	-33	N/A	257	N/A
6/30/2013	1,701	-55	N/A	256	N/A
3/31/2013	1,742	-79	N/A	253	N/A
12/31/2012	1,729	19	N/A	232	N/A
9/30/2012	1,730	118	N/A	213	N/A
6/30/2012	1,759	109	N/A	198	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei MDC ( 10.7% per jaar) ligt boven de spaarquote ( 1.2% ).

Winst versus markt: De winst van MDC ( 10.7% per jaar) zal naar verwachting sneller groeien dan de UK markt ( 14.6% per jaar).

Hoge groeiwinsten: De winst van MDC zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van MDC ( 3.6% per jaar) zal naar verwachting langzamer groeien dan de markt UK ( 3.5% per jaar).

Hoge groei-inkomsten: De omzet van MDC ( 3.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen MDC zal naar verwachting over 3 jaar laag zijn ( 6.6 %).

Mediclinic International Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased to UK£4.26

Price target increased to UK£4.09

Consensus forecasts updated

Mediclinic International plc Provides Revenue Guidance for Fiscal 2022

Mediclinic International plc (LON:MDC) Could Be Less Than A Year Away From Profitability

Recent updates

Financial Conduct Authority Cancels the Listing of Mediclinic Shares on the London Stock Exchange and Delisting of Shares from the JSE and the NSX Expects to Take Effect on 7 June 2023

Mediclinic International's Cancellation of Shares from Official List and Main Market of LSE Expected to Take on 30 May 2023; Delisting of Shares from JSE and NSX Expected to Take Effect from Commencement of Trade on 7 June 2023

Mediclinic International plc(LSE:MDC) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)

Cancellation of Listing of Mediclinic Shares on the LSE Is Expected on 26 May 2023

Mediclinic International plc (LSE:MDC) acquired Artisan Biomed.

Mediclinic International plc Approves Final Cash Dividend, Payable on 26 August 2022

Mediclinic International plc to Delist

Mediclinic International plc Approves Final Cash Dividend

Upcoming dividend of UK£0.03 per share

Here's Why We Think Mediclinic International (LON:MDC) Might Deserve Your Attention Today

Estimating The Intrinsic Value Of Mediclinic International plc (LON:MDC)

Here's Why Mediclinic International (LON:MDC) Can Manage Its Debt Responsibly

Remgro Wants Equal Partner in Possible Mediclinic Buyout

Price target increased to UK£4.26

Price target increased to UK£4.09

Mediclinic International Ordinary Shares to Be Deleted from OTC Equity

Independent Non-Executive Director recently bought UK£73k worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Mediclinic International plc to Report First Half, 2023 Results on Nov 16, 2022

High number of new directors

Mediclinic International plc to Report Fiscal Year 2022 Results on May 25, 2022

Are Investors Undervaluing Mediclinic International plc (LON:MDC) By 50%?

High number of new directors

Is Mediclinic International (LON:MDC) Using Too Much Debt?

High number of new directors

Mediclinic International (LON:MDC) Takes On Some Risk With Its Use Of Debt

First half 2022 earnings released: EPS UK£0.088 (vs UK£0.02 in 1H 2021)

High number of new directors

High number of new directors

Senior Independent Director J. Grieve has left the company

Independent Non-Executive Director Trevor Petersen has left the company

Is There An Opportunity With Mediclinic International plc's (LON:MDC) 25% Undervaluation?

Full year 2021 earnings released: EPS UK£0.092 (vs UK£0.43 loss in FY 2020)

Is Mediclinic International (LON:MDC) Using Too Much Debt?

Consensus forecasts updated

Mediclinic International plc Provides Revenue Guidance for Fiscal 2022

Full year 2021 earnings released: EPS UK£0.092 (vs UK£0.43 loss in FY 2020)

Does This Valuation Of Mediclinic International plc (LON:MDC) Imply Investors Are Overpaying?

If You Had Bought Mediclinic International's (LON:MDC) Shares Five Years Ago You Would Be Down 63%

New 90-day high: UK£3.06

What Kind Of Shareholders Hold The Majority In Mediclinic International plc's (LON:MDC) Shares?

Mediclinic International plc (LON:MDC) Could Be Less Than A Year Away From Profitability

Non-Executive Director recently sold UK£52k worth of stock

Have Mediclinic International plc (LON:MDC) Insiders Been Selling Their Stock?

Estimating The Fair Value Of Mediclinic International plc (LON:MDC)

These 4 Measures Indicate That Mediclinic International (LON:MDC) Is Using Debt Extensively

A Look At Mediclinic International's (LON:MDC) Share Price Returns

Our View On Mediclinic International's (LON:MDC) CEO Pay

First half 2021 earnings released: EPS UK£0.02

Revenue beats expectations, earnings disappoint

New 90-day high: UK£3.19

New 90-day high: UK£2.95

New 90-day low - UK£2.46

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven